Aclarion CEO Brent Ness to Attend LSI USA 2026

Rhea-AI Summary

Aclarion (Nasdaq: ACON) announced that CEO Brent Ness will attend LSI USA 2026 in Dana Point, CA, March 16-20, 2026, to meet investors and potential partners.

Mr. Ness will discuss progress advancing NOCISCAN, Aclarion’s MR spectroscopy platform using biomarkers and AI to help identify painful vs non-painful spinal discs. Investors may request 1-on-1 meetings via the provided contact emails.

News Market Reaction – ACON

-3.20%

1 alert

-3.20% News Effect

On the day this news was published, ACON declined 3.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 16-20, 2026 Meeting format: In-person 1x1 meetings

2 metrics

Conference dates March 16-20, 2026 LSI USA 2026 event schedule

Meeting format In-person 1x1 meetings LSI USA 2026 format

Market Reality Check

Price: $3.20 Vol: Volume 94,178 is 29% abov...

normal vol

$3.20 Last Close

Volume Volume 94,178 is 29% above the 20-day average of 73,215, showing moderate interest in this conference update. normal

Technical Shares at $3.44 are trading below the 200-day MA of $6.30, after a prior 52-week high of $32.94.

Peers on Argus

ACON was up 4.88% while momentum peers showed mixed moves: WORX down ~13%, ONMD ...

2 Up 2 Down

ACON was up 4.88% while momentum peers showed mixed moves: WORX down ~13%, ONMD down ~1.5%, HCTI up ~2.9%, BEAT up ~4.4%. With two peers moving higher alongside ACON, the action partly reflects broader sector dynamics rather than this conference alone.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Shareholder letter	Positive	-12.6%	Chairman outlined clinical, financial, and operational priorities and trial timelines.
Feb 03	Commercial expansion	Positive	-2.1%	Added Source Healthcare to integrate Nociscan and generate real-world evidence.
Jan 13	Equity financing	Positive	-6.9%	Closed $10.4M stock financing at $5.18, boosting cash to $21.6M and debt-free status.
Jan 08	Outlook & update	Positive	+42.1%	Provided 2026 outlook, highlighted strong scan growth and extended cash runway into H1 2027.
Jan 06	Trial enrollment	Positive	+3.7%	Announced first enrollments at new CLARITY sites and detailed enrollment targets and timelines.

Pattern Detected

Recent history shows mostly negative reactions to otherwise constructive updates and financings, with one standout rally on the 2026 outlook and operating update.

Recent Company History

Over the last few months, Aclarion has focused updates on Nociscan adoption, CLARITY trial progress, and balance-sheet strengthening. A $10.4M common-stock financing and subsequent communications emphasized a debt-free position and cash runway into 2028, yet several of these positive-toned releases saw negative next-day moves. The strong 42.09% reaction to the 2026 corporate outlook contrasts with weaker responses, framing today’s conference-attendance news as a lower-impact, awareness-focused item within this trajectory.

Market Pulse Summary

This announcement highlights Aclarion’s participation in LSI USA 2026, positioning management to mee...

Analysis

This announcement highlights Aclarion’s participation in LSI USA 2026, positioning management to meet investors and potential partners and further explain its Nociscan MR spectroscopy platform for chronic low back pain. In recent months, the company has reported CLARITY trial enrollment progress, stronger cash balances, and growing scan volumes. Investors may watch future updates on CLARITY milestones, real-world evidence generation, and continued commercial adoption as more concrete value drivers than conference attendance alone.

Key Terms

biomarkers, augmented intelligence (ai) algorithms, mr spectroscopy, medtech, +1 more

5 terms

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

augmented intelligence (ai) algorithms technical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Augmented intelligence (AI) algorithms are computer programs designed to assist and enhance human decision-making by analyzing data and providing insights. Unlike fully autonomous systems, they work alongside people, helping to identify patterns or solutions more quickly and accurately. For investors, these algorithms matter because they can improve the quality of predictions and strategies, leading to more informed and confident financial choices.

mr spectroscopy medical

"NOCISCAN, the company’s proprietary MR spectroscopy platform that leverages AI and biomarkers"

MR spectroscopy is a scientific technique that uses magnetic fields and radio waves to analyze the chemical composition of materials, including biological tissues. It helps researchers identify and measure the presence of different molecules, providing insights into health, disease, or material properties. For investors, understanding MR spectroscopy can be important when evaluating innovations in medical technology or pharmaceutical developments that may impact healthcare markets.

medtech technical

"one of the leading conferences of global MedTech innovators, investors, and industry leaders"

Medtech is the industry that designs and sells medical devices, diagnostic tools and health-related software used by doctors, hospitals and patients to prevent, detect or treat illness. Investors care because these products can drive steady revenue or rapid growth depending on regulatory approval, how widely clinicians and insurers adopt them, and the cost advantages they offer — similar to how a popular new tool can reshape a trade and its market.

healthtech technical

"LSI USA ’26 is a premier event focused on accelerating MedTech and HealthTech innovation"

Healthtech refers to companies that apply technology—such as software, sensors, telemedicine and artificial intelligence—to deliver, manage or analyze healthcare services and data, much like how banking apps digitized finance but for medical care. Investors care because healthtech can scale quickly, cut costs, create predictable revenue and unlock new markets, while also carrying specific risks from regulation, data privacy and the need for clinical validation that can affect returns.

AI-generated analysis. Not financial advice.

BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders.

During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the company’s proprietary MR spectroscopy platform that leverages AI and biomarkers to help physicians distinguish between painful and non-painful discs in patients suffering from chronic low back pain.

To schedule a 1-on-1 meeting with Mr. Ness, please email: ksmith@pcgadvisory.com.

LSI USA 2026
Dates: March 16-20, 2026
Location: Dana Point, CA
Format: In-person 1x1 Meetings

LSI USA ’26 is a premier event focused on accelerating MedTech and HealthTech innovation, bringing together investors, startups, and industry leaders.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

When will Aclarion (ACON) CEO Brent Ness attend LSI USA 2026?

He will attend LSI USA 2026 in Dana Point, CA from March 16-20, 2026. According to the company, Mr. Ness will hold in-person 1-on-1 meetings with investors and potential partners during those dates to discuss NOCISCAN progress and partnerships.

How can investors schedule a 1-on-1 meeting with Aclarion CEO Brent Ness at LSI USA 2026?

Investors can request 1-on-1 meetings by emailing ksmith@pcgadvisory.com as provided in the announcement. According to the company, that email is the contact for arranging meetings with Mr. Ness during LSI USA March 16-20, 2026.

What will Aclarion (ACON) discuss at LSI USA 2026 regarding NOCISCAN?

Aclarion will discuss continued progress advancing NOCISCAN, its MR spectroscopy platform using biomarkers and AI. According to the company, discussions will focus on clinical utility and partnership opportunities to help identify painful versus non-painful spinal discs.

Where and in what format will Aclarion (ACON) conduct meetings at LSI USA 2026?

Meetings will be held in person at LSI USA 2026 in Dana Point, California, as 1x1 meetings between March 16-20, 2026. According to the company, the format is in-person one-on-one investor and partner meetings to discuss NOCISCAN.

Who should I contact for more information about NOCISCAN from Aclarion (ACON)?

For NOCISCAN information, email info@aclarion.com as listed in the announcement. According to the company, that contact provides product details and directions to find NOCISCAN centers via the company site map.